OSAKA, Japan & CAMBRIDGE, Mass. — Takeda today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10% solution] as an intravenous immunoglobulin (IVIG) therapy to improve neuromuscular disability and impairment in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It can be...
Latest News
OSAKA, Japan & CAMBRIDGE, Mass. – Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients...
Seven years ago, when their son first started having seizures, Dean and Amy Kriebel found that their finances were stretched to the limit due to hospital bills and special adaptive equipment for young Andrew. “Just after his first birthday, he had his first seizure,” Dean Kriebel said. “Things spun out...
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs MILAN, Italy — Johnson & Johnson (NYSE: JNJ) announced today new results from...
Tampere, Finland – Researchers from Tampere University, Finland, and Izmir Institute of Technology, Turkey, have developed an in vitro cancer model to investigate why breast cancer spreads to the bones. Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Breast cancer is...
JERSEY CITY, N.J. — Tanabe Pharma America, Inc. (TPA) today announced the presentation of exploratory preclinical findings into edaravone’s activity in an ALS-relevant cell model. The data will be shared during the Motor Neurone Disease Association (MNDA) 36th International Symposium on ALS/MND, taking place in San Diego, California, from December 5-7, 2025...
Adelaide, Australia – A new approach to treating the most malignant type of brain cancer – glioblastoma – has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months. Targeted alpha therapy (TAT) is emerging as a potential additional treatment for glioblastoma (GB),...
A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute. The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by...
Vascular diseases like atherosclerosis can lead to serious complications, like heart attack or stroke. But many treatments for these diseases target systemic risk factors, such as reducing blood pressure and cholesterol, rather than repairing damaged blood vessels themselves. A new targeted nanomedicine treatment developed at the University of Chicago has...
SAN DIEGO, CA ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis, according to results of the Phase II SUMMIT trial reported by researchers at The University of Texas MD...